MediWound reaffirms 2026 revenue guidance of $24–26 mln
Company expects to begin recognizing revenue from Vericel agreement in H2 2026
Commercial supply from expanded NexoBrid facility expected in H2 2027, pending approval
Overview
Israel biotech's Q2 revenue fell but beat analyst expectations
Gross profit margin declined due to one-time facility scale-up impact
Company reaffirmed full-year 2026 revenue guidance of $24–26 mln
Result Drivers
BARDA revenue timing - Co said lower Q2 revenue and gross profit reflected timing of BARDA-funded development revenue
R&D investment - Increased research and development expenses were driven by investment in EscharEx Phase III VALUE trial
NexoBrid adoption - Vericel reported record quarterly revenue and hospital unit sales for NexoBrid, reflecting continued adoption in U.S. burn care market
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Mediwound Ltd is $31.00, about 122.9% above its August 12 closing price of $13.91
MDWD•
